Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Compared to the non-HSCT group, the post-allo-HSCT group showed a trend toward a lower 2-year cumulative relapse rate (25.5% vs. 64.3%, P = 0.149) (Fig. 1C ), with overall relapse rates of 21.1% (4/19) and 38.9% (7/18), respectively.

also in 53,322 other papers